CD38 and breast cancer: Consistent with the metabolomic results, we observed approximately 2-fold increase in the FAO rate in miR-142−/−BCR-ABL LSKs and BC CD34+CD38− cells compared respectively with miR-142+/+BCR-ABL LSKs and CP CD34+CD38− cells (Fig. 5a).